Contraceptive practices of women with epilepsy: Findings of the epilepsy birth control registry

Epilepsia

Volumn 57, Issue 4, 2016, Pages 630-637

  Herzog, Andrew G ^a   Mandle, Hannah B ^a   Cahill, Kaitlyn E ^a   Fowler, Kristen M ^a   Hauser, W Allen ^b   Davis, Anne R ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Vagelos College of Physicians and Surgeons   (United States)

^c Medical Center ^*  (United States)

Author keywords

Contraception; Epidemiology; Epilepsy; Seizures; Women

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CONTRACEPTIVE AGENT; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; ANTICONVULSIVE AGENT;

ADULT; ARTICLE; BIRTH CONTROL; COMPARATIVE STUDY; COMPLEX PARTIAL SEIZURE; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; EPILEPSY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INSURANCE; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; NEUROLOGIST; PATIENT DECISION MAKING; PRIORITY JOURNAL; UNPLANNED PREGNANCY; VASECTOMY; ADOLESCENT; CONTRACEPTION; MIDDLE AGED; PREGNANCY; PROCEDURES; REGISTER; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CONTRACEPTION; CONTRACEPTIVE AGENTS; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; REGISTRIES; YOUNG ADULT;

EID: 84959419196     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13320     Document Type: Article

References (35)

1. Pennell PB, Klein AM, Browning N, et al., Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav 2012; 24: 449-456.
2. Tomson T, Battino D, Bonizzoni E, et al., Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609-617.
3. Hernández-Díaz S, Smith CR, Shen A, et al., Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692-1699.
4. Reddy DS, Rogawski MA,. Neurosteroids-endogenous regulators of seizure susceptibility and role in the treatment of epilepsy. In, Noebels JL, Avoli M, Rogawski MA, et al. (Eds) Jasper's basic mechanisms of the epilepsies. 4th Ed. Bethesda, MD: National Center for Biotechnology Information (US), 2012. Available at: http://www.ncbi.nlm.nih.gov/books/NBK98218/. Accessed September 30, 2015.
5. Herzog AG,. Catamenial epilepsy: update on prevalence, pathophysiology and treatment from the findings of the NIH Progesterone Treatment Trial. Seizure 2015; 28: 18-25.
6. Crawford P,. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263-272.
7. Sabers A,. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 2008; 17: 141-144.
8. Herzog AG, Blum AS, Farina EL, et al., Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009; 72: 909-914.
9. Davis AR, Westhoff CL, Stanczyk FZ,. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 2011; 52: 243-247.
10. Gaffielda ME, Culwella KR, Leeb CR,. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception 2011; 83: 16-29.
11. Shavit G, Lerman P, Korczyn AD, et al., Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984; 34: 959-961.
12. Rościszewska D, Buntner B, Guz I, et al., Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986; 49: 47-51.
13. Sidhu J, Job S, Singh S, et al., The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2005; 61: 191-199.
14. Pack AM, Davis AR, Kritzer J, et al., Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity? Epilepsy Behav 2009; 14: 640-644.
15. U.S. Census Bureau. Educational attainment in the United States: 2014-detailed tables. Educational attainment. Available at: www.census.gov. Accessed June 5, 2015.
16. U.S. Census Bureau. HINC-01. Selected characteristics of households, by total money income in 2012. Current population survey, 2013 annual social and economic supplement. Available at: www.census.gov. Accessed June 5, 2015.
17. U.S. Census Bureau. Table 1. Annual estimates of the population for the United States, regions, states, and Puerto Rico: April 1, 2010 to July 1, 2013. State characteristics: vintage 2013. Available at: www.census.gov. Accessed June 5, 2015.
18. Smith JC, Medalia C,. Health insurance coverage in the United States: 2013. U.S. Census Bureau, current population reports, P60-250. Washington, DC: U.S. Government Printing Office; 2014.
19. Sabers A, Christensen J,. No effect of oral contraceptives on the metabolism of levetiracetam. Epilepsy Res 2011; 95: 277-279.
20. Pew Research Center Internet Project Survey. 2014. Available at: http://www.pewinternet.org/files/2014/02/12-internet-users-in-2014.jpg. Accessed September 30, 2015.
21. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
22. Eadie MJ,. Shortcomings in the current treatment of epilepsy. Expert Rev Neurother 2012; 12: 1419-1427.
23. Meador KJ, Penovich P, Baker GA, et al., Antiepileptic drug use in women of childbearing age. Epilepsy Behav 2009; 15: 339-343.
24. Jones J, Mosher WD, Daniels K,. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995, National Health Statistics Reports, 2012, No. 60. Available at: http://www.cdc.gov/nchs/data/nhsr/nhsr060.pdf. Accessed September 30, 2015.
25. Davis AR, Pack AM, Kritzer J, et al., Reproductive history, sexual behavior and use of contraception in women with epilepsy. Contraception 2008; 77: 405-409.
26. Mosher WD, Jones J,. Use of contraception in the United States: 1982-2008. National Center for Health Statistics. Vital Health Stat 2010; 23: 1-54.
27. Finer LB, Jerman J, Kavanaugh ML,. Changes in use of long-active contraceptive methods in the U.S., 2007-2009. Fertil Steril 2012; 98: 893-897.
28. Daniels K, Daugherty J, Jones J,. Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief, no. 173, Hyattsville, MD: National Health Statistics; 2014.
29. Bounds W, Guillebaud J,. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002; 28: 78-80.
30. Sabers A, Buchholt JM, Uldall P, et al., Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2011; 47: 151-154.
31. Zahn CA, Morrell MJ, Collins SD, et al., Management issues for women with epilepsy: a review of the literature. Neurology 1998; 51: 949-956.
32. Winterbottom J, Smyth R, Jacoby A, et al., The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: what's the evidence? Epilepsy Behav 2009; 14: 273-279.
33. Harden CL, Meador KJ, Pennell PB, et al., Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 133-141.
34. Fountain NB, Van Ness PC, Swain-Eng R, et al., Quality improvement in neurology: AAN epilepsy quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2011; 76: 94-99.
35. Centers for Disease Control and Prevention. U S. medical eligibility criteria for contraceptive use, 2010. Adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th ed. MMWR Morb Mortal Wkly Rep 2010; 59: 18.